Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsPRNewsWire • 03/19/24
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024PRNewsWire • 03/12/24
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma ConferencePRNewsWire • 03/05/24
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsPRNewsWire • 11/08/23
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023PRNewsWire • 11/03/23
Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024Seeking Alpha • 10/13/23
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023PRNewsWire • 10/11/23
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitPRNewsWire • 10/09/23
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) CongressPRNewsWire • 10/06/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 10/02/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 09/27/23
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive DisorderPRNewsWire • 09/20/23
Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim ReadoutSeeking Alpha • 09/01/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 08/25/23
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive DisorderPRNewsWire • 08/23/23
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsPRNewsWire • 08/08/23
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023PRNewsWire • 08/01/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the FirmAccesswire • 07/25/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/06/23